Alcoholic hepatitis is inflammation of the liver,
which is caused due to heavy consumption of alcohol. It can lead to serious
conditions such as fluid build-up in the abdomen, confusion, and bleeding in
the esophagus.
Looking
for more information on this market? Request
a free sample report

There is no effective treatment for severe alcoholic hepatitis. Hence,
researchers are focusing on developing combination therapies, as they are more
effective. For instance, at the University of Massachusetts Medical School,
researchers are studying a combination therapy with Kineret, Trental, and zinc sulfate. The combination showed short and long-term survival
benefits in patients with severe alcoholic hepatitis.
Phase II clinical trial is being conducted by Gilead Sciences to
evaluate the safety and tolerability ofselonsertib (GS-4997) in combination with prednisolone in
the patients. An antibiotic combined with a corticosteroid is being evaluated
by researchers by targeting the group of patients at a high risk of death due
to alcoholic hepatitis. Such developments of combination therapies to treat
severe alcoholic hepatitis are expected to drive the growth of the global
alcoholic hepatitis treatment market at a CAGR of 5.85% during the
forecast period.
Browse Full Report - http://bit.ly/2OCF2rT
No comments:
Post a Comment